ADDvise receives frame agreement from SLL at an order value of 20 + 20 MSEK

10-01-2017   Regulatory press release

IM-Medico Svenska AB, a subsidiary in the ADDvise Group, has been awarded a frame agreement for laparoscopy products from the County Council of Stockholm. The estimated value of the agreement for IM-Medico is 10 MSEK per annum. The agreement runs for two years with a two-year prolongation option.

IM-Medico Svenska AB, a subsidiary in the ADDvise Group, has been awarded a frame agreement from the County Council of Stockholm for laparoscopy products. These products are used in laparoscopy procedures with internal stapling for invasive surgery. IM-Medico has been chosen as the preferred supplier in competition with vendors such as Johnsson & Johnsson and Medtronic.

-       Rikard Akhtarzand comments the business; “Our extensive investment in the surgery segment is now paying off. To be chosen as the preferred supplier in competition with Johnsson & Johnsson and Medtronic is a major achievement for us”.

The agreement has a standstill period until January 19 2017 and starts running on June 1 2017.

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se 


Important information:
 

This information is by ADDvise required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on January 10, 2017 at 08:45 CET.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, 08-503015 50, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com

Latest press releases

Report from the extra ordinary general meeting in ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no. 556363-2115 (the "Company"), has held an extraordinary general meeting on 12 March 2025. The general meeting resolved to amend the articles of association, approve the board's resolution regarding a rights issue of shares of series A and series B, approve the board's resolution on a directed issue of warrants…

Year-end report 2024, January 1–December 31

Regulatory

The fourth quarter of 2024 showed a turnaround in organic net revenue. In December alone, we are now back at positive organic growth of 4.8%. With new long-term financial targets, we are now taking the next step in the company’s development, with a continued focus on profitable growth, stable returns and well-balanced debt.

Notice to extraordinary general meeting of ADDvise Group AB (publ)

Regulatory

ADDvise Group AB (publ), reg. no 556363–2115, hereby convenes the extraordinary general meeting on 12 March 2025 at 10:00 CET at Grev Turegatan 30 in Stockholm. Entrance and registration start at 09:30 CET. Shareholders wishing to attend the general meeting must: i)          be registered in the share register kept by Euroclear Sweden on the record…

The Board of Directors of ADDvise has resolved on a rights issue of SEK 457 million

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES), AUSTRALIA, CANADA, BELARUS, HONG KONG, JAPAN, NEW ZEALAND AND RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL,…